PAXMAN publishes newsletter with interviews on the company’s outlook in the USA and its collaboration with Teva in Mexico
PAXMAN has today published the first issue of its newsletter aimed at Swedish shareholders, investors and other interested parties.
This issue includes information on the company’s outlook in the USA, the collaboration with Teva in Mexico and the company’s efforts to enable scientific progress and strengthen the possibility to receive reimbursement for scalp cooling in the USA. To read the newsletter (initially in Swedish only), and to subscribe, follow this link:
PAXMAN’s newsletter, initially published every two months in Swedish, is a part of the company’s effort to strengthen its market communication together with the IR agency Honeybager. Every published issue of the newsletter will be available on PAXMANs Swedish website, www.paxman.se. The company will be happy to receive requests on topics for upcoming issues as well as other feedback.
For further information, please contact:
Richard Paxman, CEO
Tel: +44 7968 020641
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US)
The PAXMAN share is listed on Nasdaq First North. FNCA Sweden AB is the company’s Certified Adviser.